Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial

Background: Although biliary tract cancer (BTC) has a very aggressive nature, some patients maintain a relatively good performance status after failure with first-line treatment of gemcitabine plus cisplatin (GC). Thus, tolerable, feasible, and useful second-line treatments are needed for these pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Oh, Sung Yong, Lee, Jeeyun, Kang, Jung Hun, Lee, Hyun Woo, Lee, Myung Ah, Sohn, Byeong Seok, Hong, Ji Hyong, Park, Young Suk, Park, Joon Oh, Lim, Ho Yeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856733/
https://www.ncbi.nlm.nih.gov/pubmed/31772650
http://dx.doi.org/10.7150/jca.37610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856733/
https://www.ncbi.nlm.nih.gov/pubmed/31772650
http://dx.doi.org/10.7150/jca.37610

Ejemplares similares